Molecular Devices

Molecular Devices, LLC, located in San Jose, California, specializes in bioanalytical solutions for protein and cell biology, primarily serving life science research, pharmaceutical, and biotherapeutic development sectors. The company offers a comprehensive range of products, including microplate readers, cellular imaging systems, high-throughput screening platforms, and acquisition and analysis software. Their portfolio also features biosensors, kits, and advanced data analysis software designed to enhance research workflows and ensure data integrity. Molecular Devices enables scientists to conduct critical applications such as cell counting, protein detection, and stem cell research, ultimately accelerating the discovery of new therapeutics. With over 130,000 installations globally, the company has contributed to significant scientific advancements, evidenced by more than 25,000 peer-reviewed publications. As a subsidiary of Danaher Corporation, Molecular Devices employs nearly 1,000 skilled professionals and maintains a strong presence in the field of bioanalytical measurement solutions.

Mary Duseau

President

2 past transactions

Cellesce

Acquisition in 2022
Cellesce Ltd is a biochemical engineering company located in Cardiff, UK, specializing in cell expansion with a focus on organoids. The company provides bioprocessing technology and engineering services aimed at drug discovery and organ-on-a-chip applications. Cellesce develops, scales up, and manufactures patient-derived organoids, utilizing proprietary bioprocess and bioreactor systems. These systems enable the expansion of both normal and cancer patient-derived organoids, facilitating applications such as drug screening. By incorporating in-line sensors and real-time monitoring, Cellesce ensures precise culture conditions, enhances yield, and controls organoid size, thereby minimizing variability between batches and users. This approach supports healthcare professionals in drug efficacy testing, ultimately contributing to advancements in medical research and treatment development.

LJL Biosystems

Acquisition in 2000
LJL is developing and marketing proprietary technologies and products to accelerate and enhance the drug discovery process. LJL's proprietary integrated technology platform is comprised of instrumentation and fluorescence-based and other assay technologies designed to provide a flexible solution to the current and evolving HTS requirements of drug discovery laboratories. The drug discovery process involves several stages including target identification, compound synthesis, assay development, screening and lead optimization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.